[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100231943":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":27,"centralContacts":32,"locations":41,"responsibleParty":62,"collaborators":21,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":21,"enrollmentInfo":75,"targetDuration":21,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":21,"overallStatus":44,"whyStopped":21,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"AHS Cancer Control Alberta","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Chemotherapy with Concurrent Radiation","EXPERIMENTAL","Carboplatin and paclitaxel will be administered intravenously on Days 1 and 8 while radiation therapy is administered",[13,14],"Drug: Carboplatin and Taxol (paclitaxel)","Radiation: External Beam Radiation",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Carboplatin and Taxol (paclitaxel)","Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg\u002Fm2) intravenously on Days 1 and 8. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1. Preparation and administration of chemotherapy will be according to local site standard of care.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"RADIATION","External Beam Radiation","Patients will receive external beam radiation therapy of 30Gy\u002F10 fractions over two weeks (or reduced to 25 Gy\u002F10 fractions if acute toxicity parameters are met during the run-in) and receive carboplatin (AUC 2) and paclitaxel (50 mg\u002Fm2) intravenously on Days 1 and 8. Treatment will be planned, prescribed and delivered using standard 3D radiotherapy planning techniques to encompass the primary tumor and surrounding clinical target volume. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1.",[9],[28],{"name":29,"affiliation":30,"role":31},"Marc Kerba, MD","5872316617","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":21,"email":37},"Marilyn David","CONTACT","5872315492","marilyn.david@cancercarealberta.ca",{"name":39,"role":35,"phone":21,"phoneExt":21,"email":40},"Amy Abel","amy.abel@albertahealthservices.ca",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Tom Baker Cancer Centre","RECRUITING","Calgary","Alberta","T2N 4N2","Canada","CA",{"type":51,"coordinates":52},"Point",[53,54],-114.08529,51.05011,{"lat":54,"lon":53},[57,60],{"name":29,"role":35,"phone":58,"phoneExt":21,"email":59},"403-521-3164","marc.kerba@ahs.ca",{"name":39,"role":35,"phone":21,"phoneExt":21,"email":61},"Amy.Abel@ahs.ca",{"type":31,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Marc Kerba","MD","100231943","phase-2-chemoradiotherapy-for-advanced-esophageal-cancer-100231943",false,"NCT02297217","Chemoradiotherapy for Advanced Esophageal Cancer","A Phase 2 Study of Palliative Chemo-Radiotherapy With Carbo-Taxol in Non-Curative Cancer of the Esophagus","PaRCUS","Inclusion Criteria:\n\n1. Biopsy proven carcinoma of the esophagus.\n2. Not a candidate for radical\u002Fcurative treatment due to the advanced nature of the disease, presence of metastases, or intercurrent illness.\n3. Symptomatic patients with Mellow Dysphagia Scores of ≥ 1 i.e. able to eat only some solids.\n4. ECOG Performance status ≤ 2.\n5. Patients able to begin treatment within 14 days of signing the informed consent form.\n6. Patient is at least 18 years old.\n7. Hematological function as defined by the following laboratory parameters:\n\n   * Hemoglobin \\> 100g\u002FL\n   * Platelet count \\> 100x10E9\u002FL\n   * Absolute neutrophil count \\> 1.5x10E9\u002FL\n8. Renal function to undergo chemotherapy as defined by the following laboratory parameters:\n\n   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x the upper limit of institutional normal (≤ 5 if liver metastases)\n   * Total bilirubin ≤ 1.5x the upper limit of institutional normal\n   * Calculated creatinine clearance ≥ 50 mL\u002Fmin using the Cockcroft-Gault formula\n9. Patients capable of childbearing are using adequate contraception.\n10. Written and informed consent of patient.\n\nExclusion Criteria:\n\n1. Previous radiotherapy delivered to the chest.\n2. Synchronous active malignancies.\n3. Pregnant or lactating patients: women of child bearing potential must have a negative serum pregnancy test within 7 days of Treatment Visit 1. Women or men of child bearing potential must use effective contraception (defined by the use of two birth control methods, which can be either two barrier methods or a barrier method plus a hormonal method to prevent pregnancy). Subjects must start using birth control from the time they have signed the Informed Consent Form prior to start of therapy until 120 days post completion of study therapy or study discontinuation, which must be documented in the eCRF.\n4. Patients unfit for any treatment component, including absolute contraindications for radiotherapy or Connective Tissue Disease.\n5. Tracheo-esophageal fistula.\n6. Esophageal stents in situ.\n7. Previous chemotherapy for esophageal cancer\n8. Unable to complete surveys in English without aid of interpreter.","ALL","18 Years",{"count":76,"type":77},50,"ESTIMATED","INTERVENTIONAL",[80],"PHASE2","This study aims to show that the addition of carboplatin and paclitaxel chemotherapy to a palliative course of external beam radiation treatment improves both dysphagia relief and patient quality of life in patients with unresectable esophageal cancer.",[83],"Esophageal Cancer","2025-12-09",{"date":86,"type":87},"2025-12-16","ACTUAL",{"date":89,"type":87},"2019-11-21",{"date":91,"type":77},"2028-04-30",{"name":5,"class":6},1]